<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Factors that influence agent selection for anticoagulation in patients with acute venous thromboembolism</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Factors that influence agent selection for anticoagulation in patients with acute venous thromboembolism</h1>
<div class="graphic"><div class="figure"><div class="ttl">Factors that influence agent selection for anticoagulation in patients with acute venous thromboembolism</div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="20%"></colgroup><colgroup width="60%"></colgroup> <tbody> <tr class="divider_bottom"> <td class="subtitle1">Factor</td> <td class="subtitle1">Preferred anticoagulant</td> <td class="subtitle1">Qualifying remarks</td> </tr> <tr class="divider_bottom"> <td>Cancer</td> <td>LMWH, factor Xa inhibitors</td> <td>More so if: Just diagnosed, extensive VTE, metastatic cancer, very symptomatic; vomiting; on cancer chemotherapy.</td> </tr> <tr class="divider_bottom"> <td>Initial parenteral therapy to be avoided</td> <td>Rivaroxaban; apixaban</td> <td>VKA, dabigatran, and edoxaban require initial parenteral therapy.</td> </tr> <tr class="divider_bottom"> <td>Once daily oral therapy preferred</td> <td>Rivaroxaban; edoxaban; VKA</td> <td> </td> </tr> <tr class="divider_bottom"> <td>Liver disease and coagulopathy</td> <td>LMWH</td> <td>DOACs contraindicated if INR raised because of liver disease; VKA difficult to control and INR may not reflect antithrombotic effect.</td> </tr> <tr class="divider_bottom"> <td>Renal disease and creatinine clearance &lt;30 mL/min</td> <td>VKA</td> <td>DOACs and LMWH contraindicated with severe renal impairment. However, dosing of some DOACs can be renally adjusted, although adjustment varies with different levels of renal impairment depending on the DOAC.</td> </tr> <tr class="divider_bottom"> <td>Coronary artery disease</td> <td>VKA, rivaroxaban, apixaban, edoxaban</td> <td>Coronary artery events appear to occur more often with dabigatran than with VKA. This has not been seen with the other DOACs, and they have demonstrated efficacy for coronary artery disease. Antiplatelet therapy should be avoided if possible in patients on anticoagulants because of increased bleeding.</td> </tr> <tr class="divider_bottom"> <td>Dyspepsia or history of GI bleeding</td> <td>VKA, apixaban</td> <td>Dabigatran increased dyspepsia. Dabigatran, rivaroxaban, and edoxaban may be associated with more GI bleeding than VKA.</td> </tr> <tr class="divider_bottom"> <td>Poor compliance</td> <td>VKA</td> <td>INR monitoring can help to detect problems. However, some patients may be more compliant with a DOAC because it is less complex.</td> </tr> <tr class="divider_bottom"> <td>Thrombolytic therapy use</td> <td>UFH infusion</td> <td>Greater experience with its use in patients treated with thrombolytic therapy.</td> </tr> <tr class="divider_bottom"> <td>Reversal agent needed</td> <td>VKA, UFH, DOACs</td> <td>Reversal agents for DOACs may not be universally readily available.</td> </tr> <tr class="divider_bottom"> <td>Pregnancy or pregnancy risk</td> <td>LMWH</td> <td>Potential for other agents to cross the placenta.</td> </tr> <tr> <td>Cost, coverage, licensing</td> <td>Varies among regions and with individual circumstances</td> <td> </td> </tr> </tbody></table></div><div class="graphic_footnotes">LMWH: low molecular weight heparin; VTE: venous thromboembolism; VKA: vitamin K-dependent antagonist (ie, warfarin); DOACs: direct oral anticoagulants; INR: international normalized ratio; GI: gastrointestinal; UFH: unfractionated heparin.</div><div class="graphic_reference">Original figure modified for this publication. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest 2016; 149:315. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id="graphicVersion">Graphic 107541 Version 7.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
